Obesity and survival among patients with pancreatic cancer

JAMA

Volumn 302, Issue 16, 2009, Pages 1752-

  Goldstein, Mark R ^a   Mascitelli, Luca ^b   Pezzetta, Francesca ^c  

^a Medical Service Comando Brigata Alpina Julia ^*  (United States)

^b Ospedale di Tolmezzo ^*  (Italy)

^c Ospedale Civile di Tolmezzo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN;

CANCER CELL; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; DIABETES MELLITUS; DRUG EFFECT; GERIATRIC PATIENT; HUMAN; HYPERLIPIDEMIA; LETTER; OBESITY; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; SURVIVAL; MORTALITY; NOTE; PANCREAS TUMOR; RISK FACTOR;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; OBESITY; PANCREATIC NEOPLASMS; RISK FACTORS;

EID: 70350712065     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1510     Document Type: Letter

References (5)

1. Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009;301(24):2553-2562.
2. Kusama T, Mukai M, Iwasaki T, et al. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology. 2002;122(2):308-317. (Pubitemid 34116983)
3. Shepherd J, Blauw GJ, Murphy MB, et al; PROSPER study group; PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-1630.
4. Goldstein MR, Mascitelli L, Pezzetta F. Do statins prevent or promote cancer? Curr Oncol. 2008;15(2):76-77.
5. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137(2):482-488.